India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Friday the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States.

Lupin's Abbreviated New Drug Application for Dapagliflozin Tablets was approved by US Food and Drug Administration (FDA) as bioequivalent to Farxiga for the indications in the approved labelling.

Farxiga, a brand of biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN), is indicated for the treatment of type 2 diabetes, chronic kidney disease, and symptomatic chronic heart failure.